Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial
This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured psychotherapy and will be randomized to two psilocybin sessions to receive either a full dose (30mg or 40mg) or low dose (10mg or 15mg).
- Status
- planned
- Phase
- Phase 2
- Institution
- Brigham and Women's Hospital
- Principal investigator
- Joji Suzuki, MD
- Start date
- 2026-06-15
- End date
- 2030-02-01
- Registry ID
- NCT07296094
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.